Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name "Inavir" by Daiichi Sankyo. Biota Pharmaceuticals  and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. It is under clinical evaluations in other countries.
^Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. Suppl 1 (S1): S3–13. doi:10.1086/591851. PMID19067613.
^ abSamson, M; Pizzorno, A; Abed, Y; Boivin, G (May 2013). "Influenza virus resistance to neuraminidase inhibitors.". Antiviral research98 (2): 174–85. PMID23523943.